Micromet backs Joseph Lobacki as CCO
This article was originally published in Scrip
Jospeh Lobacki has joined biopharmaceutical company Micromet, which is developing antibody-based therapies for the treatment of cancer, as senior vice-president and chief commercial officer. Mr Lobacki has 25 years' commercial experience in the biopharmaceutical industry. From 2003 to 2011, he served as senior vice-president and general manager of transplant and oncology at Genzyme.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.